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ABSTRACT:
Predicting the clinical course of osteosarcoma patients is a crucial prerequisite 
for  a  better  treatment  stratification  in  these  highly  aggressive  neoplasms  of 
bone.  In  search  of  new  and  reliable  biomarkers  we  recently  identified  cysteine-
rich intestinal protein 1 (CRIP1) to have significant prognostic impact in gastric 
cancer and therefore decided to investigate its role also in osteosarcoma. For this 
purpose  we  analyzed  223  pretherapeutic  and  well  characterized  osteosarcoma 
samples for their immunohistochemical expression of CRIP1 and correlated 
our  findings  with  clinico-pathological  parameters  including  follow-up,  systemic 
spread  and  response  to  chemotherapy.  Interestingly  and  contrarily  to  gastric 
cancer,  we  found  CRIP1  expression  more  frequently  in  patients  with  long-term 
survival  (10-year  survival  73%  in  positive  vs.  54%  in  negative  cases,  p  = 
0.0433)  and  without  metastases  (p  =  0.0108)  indicating  a  favorable  prognostic 
effect. CRIP1 therefore seems to represent a promising new biomarker in 
osteosarcoma patients which should be considered for a prospective validation.
INTRODUCTION
Osteosarcomas are the most common primary 
malignant tumors of bone generally following an 
aggressive clinical course [1]. The high rate of systemic 
spread already at the time of diagnosis explains the 
efficacy  of  neoadjuvant  and  adjuvant  chemotherapy 
and the dismal prognosis after radical surgery alone. 
However, although 5-year survival rates of up to 50-
70% can be achieved using current treatment protocols, 
a substantial group of patients with metastatic, recurrent 
and/or refractory disease is still left without effective 
treatment options [2, 3]. Analyzing the response to 
chemotherapy histologically or screening for a set 
of distinct chromosomal aberrations as we proposed 
only recently can help in predicting the prognosis of 
osteosarcoma  patients  but  does  not  allow  a  sufficient 
risk  assessment  for  further  treatment  stratification  [4, 
5].  Identifying  patients  who  may  not  respond  to  first-
line chemotherapy or will have an increased likelihood 
of developing metastases therefore seems to be a crucial 
precondition for differentiating high and low risk patients 
and for designing more individualized therapy regimens. Oncotarget 2011; 2:  970 - 975 971 www.impactjournals.com/oncotarget
Consequently, appropriate and reliant biomarkers are 
urgently needed. 
Cysteine-rich intestinal protein 1 (CRIP1) is a 
member  of  the  LIM  family  of  zinc-finger  proteins 
which are thought to be involved in cellular growth and 
differentiation [6, 7]. In several studies, CRIP1 has been 
proposed as a novel biomarker for breast cancer and 
its precursor lesions which can be triggered by ERBB2 
overexpression [8-10]. Subsequently, upregulation 
of CRIP1 was also detected in colorectal, cervical 
and prostatic cancer whereas downregulation was 
demonstrated in pancreatic carcinoma [11-15]. In gastric 
cancer, however, we were only recently and for the first 
time able to demonstrate a pivotal prognostic impact 
for  CRIP1.  Overexpression  resulted  in  a  significantly 
shorter overall survival and was identified to represent the 
strongest prognostic variable besides nodal status [16]. 
Since the role of CRIP1 in osteosarcomas has not been 
studied so far, we investigated a set of 223 pretherapeutic 
tumor samples immunohistochemically and correlated 
our findings with clinico-pathological parameters to also 
identify potential prognostic implications of CRIP1 in 
these aggressive tumors of bone.
RESULTS
Immunohistochemical expression of CRIP1
All but four cases demonstrated strong and 
consistent immunoreactivity for vimentin. Those four 
cases were excluded from the evaluation leaving a total 
of 219 osteosarcoma cases for further analysis. CRIP1 
expression was considered positive when more than 50% 
of tumor cells were immunoreactive for the respective 
protein (Figure 1). In total, CRIP1 was evaluable in 
155/219 (71%) and considered positive in 69/155 (45%) 
cases. Drop out of samples was mainly due to cutting 
artefacts and/or lack of sufficient amounts of tumor tissue 
per punch.
Figure 1: Immunhistochemistry for CRIP1. Absent (A) or focal (< 50% positive tumor cells) immunoreactivity was considered 
negative. Strong and constant staining (B, C) or immunoreactivity in more than 50% of tumor cells (D) was regarded CRIP1 positive. All 
pictures x200.Oncotarget 2011; 2:  970 - 975 972 www.impactjournals.com/oncotarget
Correlation of CRIP1 expression with clinico-
pathological parameters
The 10-year survival rate (10-YSR) differed 
significantly between CRIP1 positive and negative cases 
(73% vs. 54%, p = 0.0433, Figure 2). Additionally, CRIP1 
positive  cases  had  a  significantly  lower  frequency  of 
systemic spread (p = 0.0108, Table 2). There were no 
statistically significant correlation between the expression 
of CRIP1 and the response to chemotherapy (Table 2).
DISCUSSION
Osteosarcoma tissue samples are rare, especially 
since resected specimens usually have undergone 
neoadjuvant  treatment  hampering  further  molecular 
analyses. Only if the material of the initial biopsy is 
not completely needed for diagnostic purposes it can be 
used for experimental studies which, thus, have to be 
carefully planned to analyze the valuable tissue samples 
as efficiently as possible. One approach to ensure optimal 
utilization of osteosarcoma samples is to construct tissue 
microarrays like the one we used in this study. Since 
the identification of novel biomarkers seems mandatory 
for  developing  better  treatment  stratifications  and  for 
recognizing patients at high risk for systemic spread or 
chemoresistance, these arrays are an essential tool for 
the analysis of large numbers of samples under the same 
technical conditions.
CRIP1 is a zinc-binding protein that was discovered 
as an intestinal-specific developmentally regulated gene 
and has subsequently been recognized in several other 
tissues and cells [6, 17]. In the last years, deregulated 
CRIP1 expression was reported to characteristically occur 
in several malignant tumors, including breast, cervical, 
prostatic, colorectal, and pancreatic cancer [9, 11, 12, 14, 
15]. Interestingly, CRIP1 was also considered a bone-
specific breast cancer metastasis gene [18, 19]. Although 
its precise function is still to be elucidated, CRIP1 
seems  to  influence  various  cellular  and  immunological 
signalling pathways involved in cellular differentiation, 
protein-protein interactions during transcription, immune 
response, and cytokine expression [6, 7]. Additionally, 
a role in ERBB2-related oncogenesis was proposed for 
CRIP1 since upregulation of CRIP1 was recorded in 
ERBB2-overexpressing carcinomas of the breast which 
generally follow an aggressive course [10]. Although this 
already indicated an indirect prognostic effect for CRIP1, 
we demonstrated only recently and for the first time a 
crucial prognostic impact for CRIP1 expression itself. In 
gastric cancer, immunohistochemical detection of CRIP1 
was associated with a significantly shorter overall survival 
and represented the most decisive prognostic factor 
besides lymph node status [16]. In the present study, 
however, we identified CRIP1 to be strongly associated 
Figure 2: Kaplan-Meier curves comparing 10-year 
survival of osteosarcomas with and without CRIP1 
expression.
Sex 208/223 (93%)1
male 106
female 102
Age at diagnosis 210/223 (94%)1
average 22.9 years
median 16.3 years
range 4-88years
Localisation 212/223 (95%)1
Femur 103
Tibia 50
Humerus 17
Fibula 11
Pelvis 11
other 20
Metastases(lung)2 202/223 (91%)1
yes (total) 89
yes (atinitial diagnosis) 24
no 113
Time to metastases average 15.6 months
Time to metastases median 12.4 months
Time to metastases range 0-79months
Follow-up 214/223 (96%)1
average 65 months
median 41.7 months
range 0-286.7months
Survival 214/223 (96%)1
died 79
alive 135
Responsetochemotherapy2 146/223 (66%)1
Good 87
Poor 59
1 X/223 (Y%) = data available in X cases (Y% ofthe total number of
cases)
2 There were no patients included w ith metastases toother organs
that did notalso have metastasestothelungs
3 Good response = < 10% vital tumor cells in the resection
specimen,poorresponse=≥10% vital tumorcells
Table 1: Patients´ characteristicsOncotarget 2011; 2:  970 - 975 973 www.impactjournals.com/oncotarget
with a favorable outcome and as a statistically significant 
negative predictor of systemic spread in osteosarcoma. 
Our  findings  thus  indicate  CRIP1  to  have  tumor  type 
specific  oncogenic  and  tumor  suppressor  properties 
needing further pathogenetic clarification. Nevertheless, 
osteosarcomas are not the first malignant tumors in which 
a tumor suppressor function of CRIP1 is highly suggestive 
since also in carcinomas of the pancreas a downregulation 
of CRIP1 has been reported [14]. However, evidence of 
prognostic impact of CRIP1 in pancreatic cancer is still 
lacking.
Taken  together,  we  identified  CRIP1  as  a  new 
and promising biomarker in osteosarcoma. Although 
a  significant  correlation  with  long-term  survival  and 
metastatic  spread  was  identified,  an  association  with 
response to chemotherapy was not. This phenomenon 
might  be  influenced  by  a  relatively  high  drop  out  of 
cases due to technical issues and available response data 
in only 66% of cases. Consequently, CRIP1 should be 
validated prospectively to proof its prognostic reliability 
and, nonetheless, a potential role in response prediction in 
osteosarcoma patients.
METHODS
Tissue samples and patients´ characteristics
All tissue samples were obtained from the archives 
of the Bone Tumor Reference Center at the University 
Hospital Basel and the Clinical Cooperation Group 
Osteosarcoma at the Helmholtz Zentrum Muenchen and 
comprised cases that were diagnosed between 1974 and 
2010. Only samples from patients without prior treatment 
were  included  in  the  study  (n  =  223).  Full  patients´ 
characteristics are presented in Table 1.
Immunohistochemistry 
Tissue  samples  (n  =  223)  were  fixed  in 
buffered  4%  formalin,  decalcified  using  EDTA 
(ethylenediaminetetraacetic acid) if required, embedded 
in paraffin, and used to construct tissue microarrays as 
described elsewhere [20]. The resulting blocks were cut 
into 3 µm sections that were transferred to glass slides 
and subsequently used for immunohistochemistry. To 
ensure proper immunoreactivity of tumor samples, 
immunohistochemistry for vimentin was performed 
according to routine protocols (Ventana BenchMark 
XT®, Roche, Basel, Switzerland; CC1 pretreatment; 
prediluted antibody, clone V9; DAB chromogen). 
Immunohistochemistry for CRIP1 was also carried out 
using an automated stainer (Ventana DISCOVERY 
XT®, Roche, Basel, Switzerland; DAB chromogen). The 
dilution used for the primary antibody against CRIP1 
(AbD Serotec, Oxford, UK) was 1:100.
Evaluation of immunohistochemistry against 
CRIP1
Immunoreactivity for CRIP1 was scored semi-
quantitatively by evaluating the number of positive 
cells over the total number of cells. Both cytoplasmic 
and nuclear staining was evaluated. In cases with more 
than one punch per tumor the average expression was 
determined for further analyses. Punches that were not 
completely enclosed on the sections or showed artefacts 
due to sectioning were excluded from the analysis.
Statistical analyses
In  order  to  determine  the  cut-off  scores  defining 
immunohistochemical CRIP1 positivity and negativity, 
receiver operating characteristic (ROC) curve analysis was 
performed with the endopoint of survival [21]. Survival 
analyses were carried out using the Kaplan-Meier and 
Log-rank (Mantel-Cox) test. The differences in protein 
expression between patients with and without metastases 
and with good and poor response to chemotherapy 
were determined using the Mann-Whitney-Test. Only 
p-values < 0.05 were considered statistically significant. 
All analyses were conducted using GraphPad Prism 5.0d 
(La Jolla, CA, USA) and SPSS 19 (IBM Corporation, 
Armonk, NY, USA).
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